Effects of the small-molecule inhibitor of integrin α4, TBC3486, on pre-B-ALL cells

Leukemia

Volumn 28, Issue 10, 2014, Pages 2101-2104

  Hsieh, Y T ^a   Gang, E J ^a   Shishido, S N ^a   Kim, H N ^a   Pham, J ^a   Khazal, S ^a   Osborne, A ^a   Esguerra, Z A ^a   Kwok, E ^a   Jang, J ^a   Bonig, H ^b   Biediger, R J ^c   Vanderslice, P ^c   Kim, Y M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c TEXAS HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; ANTINEOPLASTIC AGENT; NATALIZUMAB; TBC 3486; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; 3-(1,3-BENZODIOXOL-5-YL)-3-((((-1-((BIS(2-THIENYLMETHYL)AMINO)CARBONYL)PENTYL)AMINO)CARBONYL)AMINO)PROPANOIC ACID; THIOPHENE DERIVATIVE; UREA;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL ADHESION; CELL VIABILITY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETTER; LEUKEMIA CELL; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; STROMA CELL; SURVIVAL TIME; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; COCULTURE; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; INFLAMMATION; LEUKEMIA; METABOLISM; MOUSE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; HUMANS; INFLAMMATION; INTEGRIN ALPHA4; LEUKEMIA; MICE; NEOPLASM TRANSPLANTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; STROMAL CELLS; THIOPHENES; UREA;

EID: 84921728318     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.182     Document Type: Letter

References (10)

1. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011; 29: 591-599
2. Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D et al. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood 2013; 121: 1814-1818
3. Steinman L, Merrill JT, McInnes IB, Peakman M. Optimization of current and future therapy for autoimmune diseases. Nat Med 2012; 18: 59-65
4. Vanderslice P, Woodside DG, Caivano AR, Decker ER, Munsch CL, Sherwood SJ et al. Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin alpha4beta1. Biochem Biophys Res Commun 2010; 400: 619-624
5. Cannella B, Gaupp S, Tilton RG, Raine CS. Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis. J Neurosci Res 2003; 71: 407-416
6. Masumoto A, Hemler ME. Multiple activation states of VLA-4. Mechanistic differences between adhesion to CS1/fibronectin and to vascular cell adhesion molecule-1. J Biol Chem 1993; 268: 228-234
7. Ni H, Li A, Simonsen N, Wilkins JA. Integrin activation by dithiothreitol or Mn2 induces a ligand-occupied conformation and exposure of a novel NH2-terminal regulatory site on the beta1 integrin chain. J Biol Chem 1998; 273: 7981-7987
8. Engelhardt B. The role of alpha 4-integrin in T lymphocyte migration into the inflamed and noninflamed central nervous system. Curr Top Microbiol Immunol 1998; 231: 51-64
9. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L et al. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011; 118: 2191-2199
10. Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 2013; 33: 2169-2178.